The Semaglutide Playbook

Doing a thing, or doing the right thing?

“Pranav, we have DCGI approval. We have three brands ready. We have 400 MRs being briefed this week. But honestly? I don’t know if we’re doing the right thing or just doing a thing.”

That question, from a pharma CEO, is where The Semaglutide Playbook begins. On 20 March 2026, more than 31 companies raced to launch 55 branded generics of the same molecule. Semaglide. Semaglyn.   Semglyn. Semaglu.

Industry insiders called it a “slum of brands.”

When every company sells the same molecule, the molecule can’t differentiate anyone. The Semaglutide Playbook argues that the experience you design around it becomes the product: for the prescriber, the patient and the chemist.

What’s inside

The Landscape. The competitive map on the day of patent expiry, the Delhi High Court battle that decided it, Novo’s defensive playbook, and the pricing arithmetic behind the margins at stake.

The Six Strategy Archetypes. The Ecosystem Builder, Device Innovator, Platform Player, Alliance Architect, Volume Flooder and Regional Guerrilla. Each comes with named exemplars, why it could work, and where it breaks.

The Promotional Strategy Playbook. Seven moves that work, including indication-specific stories, the 8-archetype HCP profiling model, patient experience as a competitive moat, and the “therapy initiation concierge.” It also covers five ways to waste a launch budget.

The Stakeholder Map. Who really decides: gatekeepers, volume multipliers, emerging prescribers, the influence network, and everyone beyond the prescription pad.

The Culture-Strategy Fit. The chapter most companies skip. It explains why a brilliant strategy that doesn’t match your company’s DNA collapses by Month 6.

The Fallout Forecast. What happens from Month 0 to 24, from the euphoria phase through the shakeout to consolidation.

The Playbook. Ten moves for the leadership table, from choosing your archetype honestly to building a 36-month P&L.

Why read The Semaglutide Playbook now?

The Semaglutide Playbook was published on 21 March 2026, the day after patent expiry. It is a strategy document written in real time, not in hindsight. Six months later, its central argument has become the market’s hardest lesson: with half of patients discontinuing GLP-1 therapy within 12 months, the real battle is the sixth refill, not the first prescription.

Its frameworks go beyond semaglutide. Semaglutide is a gateway molecule. The same questions of archetype, prescriber profiling and therapy continuity will decide the tirzepatide generics, oral GLP-1s and multi-agonists that follow.

Who this is for

This playbook is for the CEO wondering whether to flood the market or focus, and the CMO weighing share of voice against share of experience. It is for the CFO stress-testing ROI, the Head of Sales deciding which doctors to target first, and the brand manager trying to differentiate what, on paper, is undifferentiable.

Go deeper

For the full story of the 2026 GLP-1 year (the price collapse, the plateau, and what 224 industry practitioners said), read The Semaglutide Playbook alongside [Indian Pharma Outlook 2026].

About the author

Pranav Kumar has spent three decades building the commercial machinery of Indian pharma. He started in territory management at Cipla and went on to lead marketing, CRM and customer experience at Dr. Reddy’s Laboratories. Through Praakamya, the consultancy he founded in 2018, he advises pharmaceutical companies on brand strategy and experience design, using the I.N.S.I.G.H.T.S. brand-planning method and his eight-archetype prescriber-profiling model. Connect with him on LinkedIn.

Product specifications